Cooley LLP
500 Boylston Street
Boston, MA
05/13/2010
4:00 PM - 7:30 PM
Emerging biotech companies are finding it difficult to identify capital to support the complex science infrastructure needed for growth. Can world-class compound companies be created without venture funding? Can we advance the science without the ponderous infrastructures of past models? Come learn new approaches and discover other options for accelerating R&D in the capital-starved markets for companies with novel science but little fuel for the runway.
Join us at Cooley's offices in downtown Boston for an afternoon of ideas, connections, strategies and cocktails as we explore new paradigms in drug development.
AGENDA
4:00 Registration/networking
4:30 Presentations/panels
6:15 Q&A Session
6:30 Networking
VC Perspective: Kevin Bitterman,
Polaris Ventures; Derek Lee, Chief Financial and Corporate Development Officer,
Talaris Advisors
Big Pharma Incubator: Wing Delatorre, M.D. Head of Business Development, Biogen Idec Innovation Incubator
Pre-clinical: Steven Richter, Ph. D, President and Scientific Director, Microtest World Class Life Sciences Services (streamlined non-clinical models)
Pre-IND to Phase 2: Mark Hurtt, M.D., Chief Medical Officer, Talaris Advisors (drug development efficiency)
CMO: Patti Seymour, Senior Consultant, BioProcess Technology Consultants (innovations in contract manufacturing out-sourcing)
IP Risks: Mike Tuscan, Cooley LLP
This event is by invitation only. For more information, please email Amelia Bashalany or call 617/937-2452.